Related Experiment Video
Updated: Feb 18, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Theranostics of Neuroendocrine Tumors
Sze Ting Lee1, Harshad R Kulkarni2, Aviral Singh2
1Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Melbourne, VIC, Australia.
Abstract:
Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life.
Insights
Somatostatin receptor imaging is key for evaluating neuroendocrine tumors (NETs). Peptide receptor radionuclide therapy (PRRT) offers improved survival and quality of life for advanced NETs with minimal toxicity.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiology
Background:
- Somatostatin receptor positron emission tomography/computed tomography (PET/CT) using 68Ga-labeled somatostatin analogs is standard for assessing receptor status in neuroendocrine tumors (NETs).
- This diagnostic approach guides therapeutic decisions, particularly for advanced or progressive NETs.
Purpose of the Study:
- To highlight the role of 68Ga-somatostatin analog PET/CT in evaluating NETs.
- To emphasize the efficacy and safety of peptide receptor radionuclide therapy (PRRT) for advanced NETs.
Main Methods:
- 68Ga-labeled somatostatin analogs for PET/CT imaging.
- Fractionated, personalized peptide receptor radionuclide therapy (PRRT).
Main Results:
- PRRT demonstrates significant benefits in progression-free and overall survival for patients with advanced or progressive NETs.
- PRRT leads to substantial improvements in clinical condition and quality of life.
- Fractionated, personalized PRRT shows good therapeutic responses without significant severe hematological or renal toxicity.
Conclusions:
- 68Ga-somatostatin analog PET/CT is crucial for NET evaluation and treatment selection.
- PRRT is an effective and safe treatment option for advanced or progressive NETs, enhancing survival and quality of life.
